Association of ustekinumab and briakinumab with major adverse cardiovascular events

References

• Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306:864 - 71; http://dx.doi.org/10.1001/jama.2011.1211; PMID: 21862748
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2012; In press http://dx.doi.org/10.1111/j.1468-3083.2012.04500.x; PMID: 22404103
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132:304 - 14; http://dx.doi.org/10.1038/jid.2011.304; PMID: 22011907
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165:652 - 60; http://dx.doi.org/10.1111/j.1365-2133.2011.10418.x; PMID: 21574983
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39:242 - 52; http://dx.doi.org/10.1111/j.1346-8138.2011.01347.x; PMID: 21955098
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144:200 - 7; http://dx.doi.org/10.1001/archdermatol.2007.63; PMID: 18283176
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al, CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580 - 92; http://dx.doi.org/10.1056/NEJMoa062382; PMID: 17287478
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al, PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665 - 74; http://dx.doi.org/10.1016/S0140-6736(08)60725-4; PMID: 18486739
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al, PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675 - 84; http://dx.doi.org/10.1016/S0140-6736(08)60726-6; PMID: 18486740
   PubMed Web of Science ®Google Scholar
• Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165:661 - 8; http://dx.doi.org/10.1111/j.1365-2133.2011.10419.x; PMID: 21574984
   PubMed Web of Science ®Google Scholar
• Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, et al, PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63:154 - 63; http://dx.doi.org/10.1016/j.jdermsci.2011.05.005; PMID: 21741220
   PubMed Web of Science ®Google Scholar
• Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26:53 - 77; http://dx.doi.org/10.1002/sim.2528; PMID: 16596572
   PubMed Web of Science ®Google Scholar
• Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002; 21:1575 - 600; http://dx.doi.org/10.1002/sim.1188; PMID: 12111921
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Toulis K. Biologic therapies for chronic plaque psoriasis and cardiovascular events. JAMA 2011; 306:2095 - , author reply 2095-6; http://dx.doi.org/10.1001/jama.2011.1660; PMID: 22089716
   PubMed Web of Science ®Google Scholar
• Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011; 165:1066 - 73; http://dx.doi.org/10.1111/j.1365-2133.2011.10525.x; PMID: 21777216
   PubMed Web of Science ®Google Scholar
• Greenland S, Salvan A. Bias in the one-step method for pooling study results. Stat Med 1990; 9:247 - 52; http://dx.doi.org/10.1002/sim.4780090307; PMID: 2343220
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164:862 - 72; http://dx.doi.org/10.1111/j.1365-2133.2011.10257.x; PMID: 21332467
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, et al, PHOENIX 1, PHOENIX 2, and ACCEPT investigators. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11:300 - 12; PMID: 22395580
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al, ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118 - 28; http://dx.doi.org/10.1056/NEJMoa0810652; PMID: 20071701
   PubMed Web of Science ®Google Scholar
• Barzi F, Patel A, Gu D, Sritara P, Lam TH, Rodgers A, et al, Asia Pacific Cohort Studies Collaboration. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007; 61:115 - 21; http://dx.doi.org/10.1136/jech.2005.044842; PMID: 17234869
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Deverly A, Moyse D, Castaigne A, Mancia G, de Leeuw PW, et al, Intervention as a Goal in Hypertension Treatment Study Group. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973 - 80; http://dx.doi.org/10.1097/00004872-200210000-00016; PMID: 12359975
   PubMed Web of Science ®Google Scholar
• Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327:1267; http://dx.doi.org/10.1136/bmj.327.7426.1267; PMID: 14644971
   PubMed Web of Science ®Google Scholar
• Empana JP, Ducimetière P, Arveiler D, Ferrières J, Evans A, Ruidavets JB, et al, PRIME Study Group. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003; 24:1903 - 11; http://dx.doi.org/10.1016/j.ehj.2003.09.002; PMID: 14585248
   PubMed Web of Science ®Google Scholar
• Hense HW, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24:937 - 45; http://dx.doi.org/10.1016/S0195-668X(03)00081-2; PMID: 12714025
   PubMed Web of Science ®Google Scholar
• Koller MT, Steyerberg EW, Wolbers M, Stijnen T, Bucher HC, Hunink MG, et al. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am Heart J 2007; 154:87 - 93; http://dx.doi.org/10.1016/j.ahj.2007.03.022; PMID: 17584559
   PubMed Web of Science ®Google Scholar
• Lenz M, Mühlhauser I. [Cardiovascular risk assessment for informed decision making. Validity of prediction tools]. Med Klin (Munich) 2004; 99:651 - 61; http://dx.doi.org/10.1007/s00063-004-1097-3; PMID: 15583875
   PubMed Web of Science ®Google Scholar
• Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pécoud A, Hayoz D, et al. Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. Int J Cardiol 2009; 133:346 - 53; http://dx.doi.org/10.1016/j.ijcard.2008.01.004; PMID: 18485502
   PubMed Web of Science ®Google Scholar
• Neuhauser HK, Ellert U, Kurth BM. A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. Eur J Cardiovasc Prev Rehabil 2005; 12:442 - 50; http://dx.doi.org/10.1097/01.hjr.0000183909.52118.9f; PMID: 16210930
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Papp KA, Ortonne J-P, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365:1586 - 96; http://dx.doi.org/10.1056/NEJMoa1010858; PMID: 22029980
   PubMed Web of Science ®Google Scholar
• Langley RGB, Papp KA, Gottlieb AB, Krueger GG, Gordon KB, Williams DA, et al. Safety Results from a Pooled Analysis of Randomized, Controlled Phase II and III Clinical Trials and Interim Data from an Open-Label Extension Trial of the Interleukin-12/23 Monoclonal Antibody, Briakinumab, in Moderate to Severe Psoriasis. Journal of European Academy of Dermatology Venereology 2012; In press http://dx.doi.org/10.1111/j.1468-3083.2012.04705.x
   Web of Science ®Google Scholar
• Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010; 37:413 - 25; http://dx.doi.org/10.1111/j.1346-8138.2010.00802.x; PMID: 20536646
   PubMed Web of Science ®Google Scholar
• Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 2011; 63:1729 - 35; http://dx.doi.org/10.1002/acr.20627; PMID: 21905258
   PubMed Web of Science ®Google Scholar
• Oxman AD, Clarke MJ, Stewart LA. From science to practice. Meta-analyses using individual patient data are needed. JAMA 1995; 274:845 - 6; http://dx.doi.org/10.1001/jama.1995.03530100085040; PMID: 7650811
   PubMed Web of Science ®Google Scholar
• Concato J. Is it time for medicine-based evidence?. JAMA 2012; 307:1641 - 3; http://dx.doi.org/10.1001/jama.2012.482; PMID: 22511693
   PubMed Web of Science ®Google Scholar
• Kent DM, Shah ND. Risk models and patient-centered evidence: should physicians expect one right answer?. JAMA 2012; 307:1585 - 6; http://dx.doi.org/10.1001/jama.2012.469; PMID: 22511683
   PubMed Web of Science ®Google Scholar